Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.43 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DBH | P09172 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9340459 | 0.82 | CES2 (0.61) | CES2CES1ALDH1A1KDM4EKMT2A | |
| SCHEMBL3501242 | 0.82 | CES2 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12780262 | 0.81 | CES2 (0.42) | CES2CES1KDM4EDBHGAA | |
| SCHEMBL11916367 | 0.80 | HSP90AB1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1830213 | 0.80 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29378476 | 0.80 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2426987 | 0.79 | DGAT1 (0.59) | CES2CES1ALDH1A1KDM4EGAA | |
| SCHEMBL12780514 | 0.79 | CES2 (0.41) | CES2CES1KDM4EDBHGAA | |
| SCHEMBL12438055 | 0.79 | TRPA1 (0.47) | CES2CES1ALDH1A1GAAPPARG | |
| SCHEMBL30448279 | 0.79 | DGAT1 (0.59) | CES2CES1ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011040510-A1 | INDAZOLE ANALOGUE | 旭化成ファーマ株式会社 (JP) | 2011-04-07 | — | — | WO | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| WO-2010041569-A1 | INDAZOLE COMPOUND | 旭化成ファーマ株式会社 (JP) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | CA12 4507/4885CA1 4210/4885CA2 2243/4885 |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | CA12 4774/4885CA1 4663/4885CA2 4295/4885 |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | CA12 4173/4885CA1 2273/4885CA2 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.